Clinical Trials

Sponsor: NRG

Sponsor Study ID: NRG-BN010

Study Title: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Sterotactic Radiotherapy in Recurrent Glioblastoma

NCT Number: NCT04729959

Phase: II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Brain and Nervous System

Study Objectives: This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment (recurrent). The goal of this study is to change a tumor that is unresponsive to cancer therapy into a more responsive one. Therapy with fractionated stereotactic radiotherapy in combination with tocilizumab may suppress the inhibitory effect of immune cells surrounding the tumor and consequently allow an immunotherapy treatment by atezolizumab to activate the immune response against the tumor. Combination therapy with tocilizumab, atezolizumab and fractionated stereotactic radiation therapy may shrink or stabilize the cancer better than radiation therapy alone in patients with recurrent glioblastoma.



For more information about the trial above please contact the study team:

Study Documents
(MUSC NetID required for document access)